Initiation of a Phase III Clinical Study of BON-001 for Nausea and Vomiting of Pregnancy in Japan

What happened: Mochida Pharmaceutical and Duchesnay announced the start of a Phase III clinical study of BON-001 for nausea and vomiting of pregnancy in Japan. The study is a multicenter, randomized, double-blind, placebo-controlled trial in pregnant women. Key numbers: Phase III study; agreement signed December 2025; combination marketed in 45 countries; more Why it matters: No drug is approved in Japan for this indication, and Mochida said the study is a step toward addressing the unmet medical need. The companies expect the product's introduction to also address "drug loss" in Japan. Market: +1.5% today ($39.43), -22.2% YTD, 0.8x vol — as of 08:00 UTC

Mochida Pharmaceutical and Duchesnay announced the start of a Phase III clinical study of BON-001 for nausea and vomiting of pregnancy in Japan. The study is a multicenter, randomized, double-blind, placebo-controlled trial in pregnant women.

No drug is approved in Japan for this indication, and Mochida said the study is a step toward addressing the unmet medical need. The companies expect the product's introduction to also address "drug loss" in Japan. Market: +1.5% today ($39.43), -22.2% YTD, 0.8x vol — as of 08:00 UTC